Paper41997128
Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature.
Subudhi S and 2 others. Cell, 2026. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature. Papers, record 41997128. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41997128
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neovascularization, Pathologic | Major topic |
| Neoplasms | Major topic |
| Angiogenesis Inhibitors | Major topic |
| Angiogenesis | Major topic |
| Humans | |
| Animals | |
| Tumor Microenvironment | |
| Immunotherapy |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 NS118929 | NINDS NIH HHS | United States | R01NS118929 | PubMed | NIH RePORTER |
| U01 CA224348 | NCI NIH HHS | United States | U01CA224348 | PubMed | NIH RePORTER |
| R01 CA259253 | NCI NIH HHS | United States | R01CA259253 | PubMed | NIH RePORTER |
| R35 CA197743 | NCI NIH HHS | United States | R35CA197743 | PubMed | NIH RePORTER |
| R01 CA269672 | NCI NIH HHS | United States | R01CA269672 | PubMed | NIH RePORTER |
| U01 CA261842 | NCI NIH HHS | United States | U01CA261842 | PubMed | NIH RePORTER |
References369
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27589843 | Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. | Oncotarget | 2016 | https://conductscience.org/library/papers/27589843 | PubMed |
| 2 | 29508855 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/29508855 | PubMed |
| 3 | 37879536 | A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. | J Thorac Oncol | 2024 | https://conductscience.org/library/papers/37879536 | PubMed |
| 4 | 31628560 | Models and molecular mechanisms of blood vessel co-option by cancer cells. | Angiogenesis | 2020 | https://conductscience.org/library/papers/31628560 | PubMed |
| 5 | 40628539 | Pericyte phenotype switching in cancer. | Trends Cancer | 2025 | https://conductscience.org/library/papers/40628539 | PubMed |
| 6 | 37059069 | Cancer neuroscience: State of the field, emerging directions. | Cell | 2023 | https://conductscience.org/library/papers/37059069 | PubMed |
| 7 | 35120598 | Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. | Cancer Cell | 2022 | https://conductscience.org/library/papers/35120598 | PubMed |
| 8 | 9008168 | Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. | Cell | 1997 | https://conductscience.org/library/papers/9008168 | PubMed |
| 9 | 26367079 | Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. | Biochim Biophys Acta | 2015 | https://conductscience.org/library/papers/26367079 | PubMed |
| 10 | 17021318 | Ranibizumab for neovascular age-related macular degeneration. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17021318 | PubMed |
| 11 | 38444610 | FOXO1 stimulates tip cell-enriched gene expression in endothelial cells. | iScience | 2024 | https://conductscience.org/library/papers/38444610 | PubMed |
| 12 | 25806273 | Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology. | Transl Lung Cancer Res | 2013 | https://conductscience.org/library/papers/25806273 | PubMed |
| 13 | 40540467 | Active peptides of TSP-1 inhibit retinal angiogenesis through the CD36 pathway in a rat model of choroidal neovascularization. | PLoS One | 2025 | https://conductscience.org/library/papers/40540467 | PubMed |
| 14 | 36823172 | Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas. | Nat Commun | 2023 | https://conductscience.org/library/papers/36823172 | PubMed |
| 15 | 18802153 | Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18802153 | PubMed |
| 16 | 19763275 | VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. | PLoS One | 2009 | https://conductscience.org/library/papers/19763275 | PubMed |
| 17 | 22127927 | Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. | Cancer Res | 2012 | https://conductscience.org/library/papers/22127927 | PubMed |
| 18 | 39400127 | Spatial Multiomics Reveals Intratumoral Immune Heterogeneity with Distinct Cytokine Networks in Lung Cancer Brain Metastases. | Cancer Res Commun | 2024 | https://conductscience.org/library/papers/39400127 | PubMed |
| 19 | 39019408 | Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors. | Biochim Biophys Acta Rev Cancer | 2024 | https://conductscience.org/library/papers/39019408 | PubMed |
| 20 | 8756616 | Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. | Mol Cell Biol | 1996 | https://conductscience.org/library/papers/8756616 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42974100 | Cancer-associated fibroblasts and innate immune cells: orchestrators of the immunosuppressive tumor microenvironment. | Front Immunol | 2026 | https://conductscience.org/library/papers/42974100 | PubMed |
| 42961010 | Vascular normalization confers an endothelial immune suppressive gene expression profile. | Mol Oncol | 2026 | https://conductscience.org/library/papers/42961010 | PubMed |
| 42862474 | Linking preclinical models with functional imaging and artificial intelligence to decode tumor angiogenesis. | Pharmacol Rep | 2026 | https://conductscience.org/library/papers/42862474 | PubMed |
| 42699645 | Transrectal ultrasonographic parameters combined with total serum exosomes for the assessment of bone metastases in prostate cancer. | Open Life Sci | 2026 | https://conductscience.org/library/papers/42699645 | PubMed |
| 42543810 | Glioma-Associated Microglia Augment Neuronal Hyper-Excitability in Glioma. | Brain Tumor Res Treat | 2026 | https://conductscience.org/library/papers/42543810 | PubMed |
| 42192869 | Hypoxia Impairs CD8+ T Cell Fitness and Is Associated with a Dysfunctional CD8+ T Cell State in Pancreatic Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42192869 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41997128
GET https://conductscience.org/api/papers/v1/41997128/references?page=2